GlassScriptPhysician profile
Jeffrey A Lefkovitz
NPI 1184661886
$163,973.98
in general payments reported to CMS, 2019-2025
38 companies · $14K in 2025
The $14K reported for 2025 was more than what 94% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $21K · 2020: $9,067 · 2021: $19K · 2022: $15K · 2023: $13K · 2024: $73K · 2025: $14K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $79K · Food and Beverage: $11K · Travel and Lodging: $5,440 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $4,275 · Education: $90.82.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $79,155.00 |
| Food and Beverage | $11,107.47 |
| Travel and Lodging | $5,439.85 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $4,275.00 |
| Education | $90.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $66,589.21 | 2024-2025 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $35,556.92 | 2019-2025 | Trulance, Xifaxan, Relistor |
| Abbvie INC. | $32,845.98 | 2019-2025 | |
| Allergan, INC. | $9,324.15 | 2019 | |
| Pfizer INC. | $8,151.36 | 2019-2024 | |
| Janssen Biotech, INC. | $4,370.53 | 2019-2025 | Stelara, Tremfya, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $2,121.49 | 2019-2025 | Entyvio |
| Qol Medical, LLC | $1,113.13 | 2019-2025 | Sucraid, Sucraid |
| Celgene Corporation | $825.93 | 2021-2024 | Zeposia |
| Janssen Scientific Affairs, LLC | $552.33 | 2020-2025 | |
| Genzyme Corporation | $464.10 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $235.57 | 2023 | Zeposia |
| Regeneron Healthcare Solutions, INC. | $181.81 | 2023-2025 | Dupixent |
| Ironwood Pharmaceuticals, INC | $175.22 | 2020-2023 | Linzess |
| Lilly USA, LLC | $151.77 | 2024-2025 | Omvoh |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Lefkovitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.